Detoxification of the Liver In PSC (Dolphin)

Primary Sclerosing Cholangitis Clinical Trial

— DOLPHIN  

Official title:

Detoxification of the Liver in Primary Sclerosing Cholangitis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05835505
• Other study ID #: 2023P000535
• Status: Recruiting
• Phase: Phase 2
• Start date: December 12, 2023
• Est. completion date: December 1, 2025

Study information

• Verified date: December 2023
• Source: Brigham and Women's Hospital
• Contact: Joshua Korzenik, MD
• Phone: 617 732-6389
• Email: jkorzenik[@]bwh.harvard.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a clinical trial being done to investigate the efficacy of drug BRS201 as a treatment in patients with primary sclerosing cholangitis. Participation in this study will take 8 weeks long and the study is structured as a cross-over study in which participants will take the study drug for 4 weeks and a placebo drug for 4 weeks in a randomized order in the form of an oral medication. Participation may also involve receiving an IV dose of the medication. The study will require participants to attend 9 study visits, all of which will be remote. Participation will involve taking an oral medication twice daily, tracking the medication in a log, and getting blood drawn and giving a stool sample for a few lab tests throughout the study. For the lab tests, a research nurse will visit the participant in-home for the convenience of the participant.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 28
• Est. completion date: December 1, 2025
• Est. primary completion date: September 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• A diagnosis of PSC for at least 6 months based upon cholangiography (ERCP or MRCP) demonstrating intrahepatic and/or extrahepatic biliary strictures, beading or irregularity consistent with PSC.

• ALP > 1.5 times the upper limit of normal (ULN) at screening.

• Subject must either be on a stable dose of ursodeoxycholic acid for > 6 months prior to screening or have been discontinued > 4 weeks prior to screening (enrollment of patients who are on UDCA will be limited to 60% of all enrolled patients).

Exclusion Criteria:

• Anticipated need for liver transplant within one year as determined by Mayo PSC risk score

• Evidence of decompensated liver disease such as variceal bleeding, ascites, or hepatic encephalopathy.

• Evidence of advanced liver disease including MELD score > 10, bilirubin > 3.0, platelet count < 100,000; or INR > 1.4

• Concomitant chronic liver disease including alcohol related liver disease, chronic hepatitis B or C infection, haemochromatosis, Wilson's disease, alpha1-antitrypsin deficiency, non-alcoholic steatohepatitis, autoimmune hepatitis, or primary biliary cholangitis

• Secondary causes of sclerosing cholangitis

• Patients who have a confirmed malignancy or cancer within 5 years except non-melanoma skin cancers

• Treatment with any investigational agents, within two months or 5 half-lives of the investigational product, whichever is longer.

• Active illicit drug or more than moderate alcohol consumption.

• Evidence of bacterial cholangitis within 6 months of enrollment

• In patients with Ulcerative Colitis, or, if Crohn's disease, a need for additional therapy at time of screening.

• Chronic kidney injury (eGFR < 60)

• Pregnancy or lactation

• Uncontrolled hypertension with a systolic BP > 140 and a systolic BP > 90

• Prohibited medications: current use of vitamin C and prednisone

• Patients with a history or risk of cardiovascular conditions, including arrhythmia, long QT syndrome, congestive heart failure, stroke, or coronary artery disease

• Patients with a history of kidney stones

• Congenital or acquired immunodeficiencies

• Other comorbidities including: diabetes mellitus, systemic lupus

• An episode of acute cholangitis within 4 weeks of screening

Related Conditions & MeSH terms

• Cholangitis
• Cholangitis, Sclerosing
• Primary Sclerosing Cholangitis

Intervention

Drug:
• BRS201
Groups 1, 2, 3, and 4 will all contain 7 subjects each, with each subject receiving active study drug and placebo in a randomized order; half will receive the placebo first for four weeks followed by active treatment for four weeks, while the other half will receive active treatment for four weeks followed by placebo for four weeks.
• Placebo
Groups 1, 2, 3, and 4 will all contain 7 subjects each, with each subject receiving active study drug and placebo in a randomized order; half will receive the placebo first for four weeks followed by active treatment for four weeks, while the other half will receive active treatment for four weeks followed by placebo for four weeks.

Locations

Country	Name	City	State
United States	Brigham and Women's Hospital	Chestnut Hill	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Brigham and Women's Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Alkaline Phosphatase (ALP) Test Result	The primary endpoint for this study is the capacity of BRS201 to normalize alkaline phosphatase levels from baseline (week 0) compared to end of active treatment (4 weeks).	4 weeks